Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Net Cash Flow (2023 - 2025)

CG Oncology's Net Cash Flow history spans 3 years, with the latest figure at -$12.6 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 105.9% year-over-year to -$12.6 million; the TTM value through Dec 2025 reached -$224.5 million, down 190.25%, while the annual FY2025 figure was -$224.5 million, 190.25% down from the prior year.
  • Net Cash Flow reached -$12.6 million in Q4 2025 per CGON's latest filing, down from $30.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $213.7 million in Q4 2024 to a low of -$215.6 million in Q1 2025.
  • Average Net Cash Flow over 3 years is -$4.6 million, with a median of -$7.3 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: skyrocketed 10745.59% in 2024, then plummeted 411.55% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at -$2.0 million in 2023, then surged by 10745.59% to $213.7 million in 2024, then plummeted by 105.9% to -$12.6 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Net Cash Flow are -$12.6 million (Q4 2025), $30.5 million (Q3 2025), and -$26.8 million (Q2 2025).